All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Gifts from Walther, Regenstrief Foundations Create Cancer Informatics Chair at IU Simon Comprehensive Cancer Center

March 14th 2023

Gifts totaling $3 million will create an endowed chair in cancer informatics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Adjuvant Targeted Therapies Could Continue to Shift the Treatment Paradigm in NSCLC

March 14th 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 13th 2023

The FDA has approved nelarabine for injection for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, according to an announcement from Shorla Oncology.

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

Survey Reveals Importance of Precise PV Treatment Guidelines and Research

March 13th 2023

Heterogeneous patterns of polycythemia vera management indicate the need for continued research in this disease and increased guideline specificity across treatment centers in Italy.

Florida Cancer Specialists & Research Institute a Top Performer in the Center for Medicare & Medicaid Innovation’s Oncology Care Model

March 13th 2023

Florida Cancer Specialists & Research Institute, LLC, a consistent top performer among the 126 U.S.-based oncology practices that participated in the Center for Medicare & Medicaid Innovation Oncology Care Model, shares its results in the payment and delivery model’s final wave which ended in June 2022 in a newly released case study.

FDA Receives Type A Meeting Request for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma

March 13th 2023

Soligenix has submitted a Type A meeting request to the FDA to discuss the contents of a refusal to file letter from the regulatory agency regarding the new drug application for synthetic hypericin for the treatment of early-stage cutaneous T-cell lymphoma.

Media Training Helps Investigators, Institutions Shine

March 13th 2023

Here are 5 tips and tricks to help you shine when the spotlight is on you.

AB011 Plus CAPOX Demonstrates Preliminary Safety, Efficacy in Advanced Gastric/GEJ Cancer

March 13th 2023

The combination of AB011 and capecitabine/oxaliplatin was found to have a manageable safety profile and to showcase early clinical benefit when used as first-line treatment in patients with gastric cancer or gastroesophageal junction adenocarcinoma.

It’s the Intensity, Not the Hours, That Makes Fellowship Challenging

March 12th 2023

Kevin Raskin, MD, discusses time management, the importance of taking time off, and teaching fellows how to listen to their inner voice.

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

March 11th 2023

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

March 10th 2023

Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.

A Primer on Job Hunting

March 10th 2023

Although the formal process of investigating a job takes time and effort, the reality is that you started interviewing for your first job on the first day of your fellowship.

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

$8 million gift establishes research fund, endowed position for bile duct cancer at IU

March 10th 2023

IU School of Medicine alumnus Kip E. Virts, MD, has made an $8 million estate gift to support bile duct cancer research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

China’s NMPA Accepts BLA for Enfortumab Vedotin in Locally Advanced/Metastatic Urothelial Cancer

March 10th 2023

The Center for Drug Evaluation of the China National Medical Products Administration has accepted the biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.

Pembrolizumab Plus Chemotherapy Meets OS End Point in Advanced Malignant Pleural Mesothelioma

March 10th 2023

First-line treatment with the combination of pembrolizumab and chemotherapy generated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Will Immunotherapy Become a Standard of Care for Glioblastoma?

March 10th 2023

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.